EGFR and lung carcinoma: Additionally, Lin et al. (Lin et al. 2023) found that metabolic reprogramming mediated by the IGF2BP3-COX6B2 axis plays a key role in the development of acquired resistance to EGFR inhibitors in lung cancer.